Tyra Biosciences, Inc. TYRA R2KR3KPHARMA
Company Overview
Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +90.23% |
| 6 Months: | -45.60% |
| 3 Months: | -34.16% |
| 1 Month: | -8.75% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.29 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 48.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TYRA Tyra Biosciences, Inc. R2KR3KPHARMA | 20.45 | -8.56 | $1.41B | 0.00% | -50.19% | -45.31% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,273.46 | 42.83 | $1.14T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 263.81 | 30.60 | $635.76B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.64 | 80.69 | $504.76B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 418.09 | 26.85 | $375.28B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 145.27 | 116.22 | $358.41B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 151.12 | 22.83 | $287.24B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 171.49 | 25.63 | $265.96B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 673.82 | 36.30 | $249.14B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | - | - | -2.33M | - | -4.21M | -5.51M | -6.64M | -14.83M | -15.43M | -13.64M | -14.33M | -16.01M | -23.96M | -22.32M | -23.53M | -28.60M | -31.85M | -31.45M | -32.94M | -42.00M | -49.00M |
| Net Income | -1.47M | -1.84M | -2.34M | -3.69M | -4.21M | -5.51M | -6.64M | -14.83M | -15.10M | -12.51M | -11.88M | -13.27M | -21.15M | -18.19M | -18.70M | -24.02M | -28.15M | -28.10M | -29.87M | -39.30M | -45.56M |
| Diluted EPS | - | - | - | - | - | -2.43 | -0.72 | -0.36 | -0.36 | -0.30 | -0.28 | -0.31 | -0.49 | -0.35 | -0.32 | -0.41 | -0.47 | -0.47 | -0.50 | -0.64 | -0.69 |
| R&D Expense | - | - | 1.86M | - | 3.52M | 4.38M | 5.48M | 9.64M | 12.05M | 10.91M | 10.41M | 12.16M | 19.27M | 17.20M | 18.00M | 22.70M | 24.96M | 24.31M | 25.47M | 33.47M | 39.20M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Income | -9.30M | -26.29M | -58.93M | -79.94M | -104.18M | -132.76M |
| Net Income | -9.34M | -26.29M | -55.33M | -69.13M | -86.48M | -119.95M |
| Diluted EPS | - | -1.91 | -1.32 | -1.62 | -1.51 | -2.01 |
| R&D Expense | 7.20M | 20.64M | 43.01M | 62.52M | 80.08M | 102.93M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 16.01M | - | 266.18M | 225.86M | 363.56M | 282.61M |
| Current Assets | - | - | - | 257.29M | 211.67M | 347.46M | 265.45M |
| Cash & Equivalents | - | 15.22M | - | 251.21M | 58.01M | 91.97M | 77.39M |
| Inventory | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - |
| Total Liabilities | - | 2.00M | - | 8.35M | 21.59M | 20.41M | 23.43M |
| Current Liabilities | - | 1.86M | - | 5.70M | 15.33M | 14.59M | 18.09M |
| Long Term Debt | - | - | - | - | - | - | - |
| Total Debt | - | - | - | 2.62M | 6.50M | 6.22M | 5.81M |
| Total Equity | -4.74M | -13.64M | - | 257.83M | 204.26M | 343.15M | 259.18M |
| Shares Outstanding | - | - | - | 42.35M | 43.02M | 50.75M | 53.71M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.76M | -23.75M | -50.28M | -50.14M | -69.77M | -95.14M |
| Investing Cash Flow | -312.00K | -645.00K | -559.00K | -144.60M | -98.40M | 72.46M |
| Financing Cash Flow | 23.43M | 311.35M | 632.00K | 1.54M | 202.14M | 8.10M |
| Capital Expenditure | -312.00K | -661.00K | -559.00K | -770.00K | -664.00K | -141.00K |
| Free Cash Flow | -8.07M | -24.41M | -50.84M | -50.91M | -70.44M | -95.28M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - |
| ROE % | 68.5% | - | -21.5% | -33.8% | -25.2% | -46.3% |
| ROCE % | -65.7% | - | -22.6% | -38.0% | -29.9% | -50.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | RA Capital Management, L.P. | 20.44% | 12.20M | $243.24M |
| 2 | FMR, LLC | 14.95% | 8.92M | $177.88M |
| 3 | Jupiter Topco LLC | 7.29% | 4.35M | $86.79M |
| 4 | Alta Partners Management Company, L.P. | 6.41% | 3.82M | $76.24M |
| 5 | Nextech Invest, Ltd. | 5.95% | 3.55M | $70.86M |
| 6 | TCG Crossover Management, LLC | 5.44% | 3.25M | $64.78M |
| 7 | Blackrock Inc. | 5.08% | 3.03M | $60.46M |
| 8 | Price (T.Rowe) Associates Inc | 4.66% | 2.78M | $55.48M |
| 9 | State Street Corporation | 3.59% | 2.14M | $42.68M |
| 10 | Commodore Capital Lp | 3.14% | 1.88M | $37.39M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TYRA
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE1vdy1MYjJDcEE3ajNGUUNpaUw5eHpURllmMzhIMm5oU09YS0UzczNQemQtY3pUYXlXQzdWMUFHamFKT183NGVvVzVyNHdqaUk4OVE?oc=5" target="_blank">Tyra Biosciences, Inc. (TYRA) stock price, news, quote a…
TYRA 261120 30.00P (TYRA261120P30000) Stock Options Chain | Quotes & News - Moomoo
<a href="https://news.google.com/rss/articles/CBMiX0FVX3lxTFA0WUJSYzlxc0IzMGdPQ19KRE5wWnJiSEFmVlloTkxfOHU2SUJnZEpfb0U3S21icU9PZnJPYW8xLVpTVUlpMS1OR1FHcDNIXzA1ZHB0a3duZWhOY0FlTF9B?oc=5" target="_blank">TYRA 261120 30.00P (TYRA261120P30000) S…
Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stock - Fierce Biotech
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQdnowOGZpeVREOGVPMVFuWnVpUWZQa000V1pzamhBYmotZ0FEMEFsTEhJV1U0XzMyYkkxR29QSVlCT0N3a1ZNLVNjMmtSS21CM0JsU0dFY0x5dHc1MlhQemhHeWZPT25ScWhPMTZ3ODFINXVHV3pOb24wVkt0YWw5REQ0ZU91Z19LcTIxVG…
Tyra Biosciences, Inc. Rings the Nasdaq Stock Market Opening Bell - Nasdaq
<a href="https://news.google.com/rss/articles/CBMikwFBVV95cUxPVXMxUmJaM3VrQjljanBWUDhCamg0RVVrejhfMWpCaXJEY0YybFJmT1FwbGhDTHpvRmVQcUY4OWdtSGdfUEVHd1FuQmdxRF9lLU5ka0V4QzhnWmlkU0hNQVgtLTBGZTBrZUR1VGE2ZUFlSmVia1dlbTBnNjlMUTY1MUJJT1F3T2dMci1sc0…
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxNLV9jM2NhRVByNjNrRVQ2ejhaNEZOZzN6VFJYekdiYXduMlQyZHl0djlZd2NsQmNGMXV2amxPU29FbUtoZjV3R3FaR0E1VVdZZ0p5SE80ZEVwak8ta0tiUHhDYjFkWk9fY2hOUGhFMXZteHVfNXo5YThiNTNEY3dyRzg1M2R2Y1BwR0Etam…
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNZE0wck5lRzFoNE8yNkI1WlJGTGR1S0VLeHBzYWNfRkJETXdzUmo0ZEZ1WWlFOTl4MG9FLWY0cks3dEpyalRIMllrTDViMXZoUFlXbjJHU0p2Y3VtZ1dzekJ1Q0lmUFhyempzSkx5Nm5Gb0V1MTI3OFJMMkZyQnd4WUZlSmtzZEh5N1Zhd1…
TYRA — Frequently Asked Questions
What is the current share price of Tyra Biosciences, Inc. (TYRA)?
As of 2026-10-23 16:27 PDT, Tyra Biosciences, Inc. (TYRA) trades at $20.45 on NasdaqGS. Its 52-week range is $10.20 to $39.61.
What is the market capitalisation of TYRA?
Tyra Biosciences, Inc. (TYRA) has a market capitalisation of $1.41B on NasdaqGS.
What is the P/E ratio of TYRA?
TYRA trades at a trailing price-to-earnings (P/E) ratio of -8.56. The industry average P/E is 25.45. Its price-to-book (P/B) ratio is 4.34.
What is the return on equity (ROE) of TYRA?
TYRA has a return on equity (ROE) of -45.31%. Its return on capital employed (ROCE) is -50.19%.
Is TYRA a good stock to buy?
This page provides a data-driven analysis of Tyra Biosciences, Inc. (TYRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.